drugset / Trial / NCT05223829
Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder
Phase 1
Active not recruiting
25 enrolled
Yale University
National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collabSage Therapeutics · collab
NaSingle-groupOpen-labelTreatment
Summary
For this protocol, the investigators plan to collect pilot data to: 1. establish the feasibility and safety of administering brexanolone to individuals with concurrent Posttraumatic Stress Disorder (PTSD) and Alcohol Use Disorder (AUD).
Timeline
- Start
- 2023-08-01
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brexanolone | Unknown | 90 ug/kg | Intravenous |